Minocycline 24 hour (Solodyn®)


Indications for Prior Authorization:

  • Acne vulgaris

All of the following must be met as a condition for coverage (must include chart note documentation as supporting information):

  • Patient must have tried/failed generic minocycline AND generic doxycycline, with chart note support of reason for treatment failures (i.e., gastrointestinal side effects); note treatment failure due to ineffectiveness of minocycline or doxycycline is not considered towards Solodyn prior authorization approval
  • Must be prescribed/consulted by a dermatologist
  • Current weight is required

This Medication is Not Approvable for the following condition(s):

  • Any condition not listed above as an approved indication

The extended release product (Solodyn) is not FDA indicated for the following:

  • Acute intestinal amebiasis
  • Actinomycosis
  • Anthrax
  • Asymptomatic carriers of Neisseria meningitidis/li>
  • Campylobacter
  • Cholera
  • Clostridium
  • Gram-negative infections
  • Listeriosis
  • Mycobacterial infection
  • Ophthalmic infections
  • Relapsing fever
  • Respiratory tract infections
  • Rickettsial infections
  • Sexually transmitted diseases
  • Skin and skin structure infections>
  • Urinary tract infections
  • Vincent infection
  • Yaws>
  • Zoonotic infections


Extended release

  • Acne (inflammatory, non-nodular, moderate to severe): 1 mg/kg once daily for 12 weeks
  • Higher doses have not shown to be of additional benefit and may be associated with more acute vestibular adverse reactions
Minocycline ERa (Solodyn) Tablets Dosing
  Tablet strength
  Actual dose
45 to 49 kg
45 mg
1 to 0.92 mg/kg
50 to 59 kg
55 mg
1.1 to 0.93 mg/kg
60 to 71 kg
65 mg
1.08 to 0.92 mg/kg
72 to 84 kg
80 mg
1.11 to 0.95 mg/kg
85 to 96 kg
90 mg
1.06 to 0.94 mg/kg
97 to 110 kg
105 mg
1.08 to 0.95 mg/kg
111 to 125 kg
115 mg
1.04 to 0.92 mg/kg
126 to 136 kg
135 mg
1.07 to 0.99 mg/kg
aER = extended release.


Six months (maximum effect may take upwards of 3-6 months)


Last review date: July 25, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar